You Were Quick to Write It Off: Israeli Company Beats Forecasts and Soars

Teva reported better-than-expected second-quarter results, raised its 2026 revenue forecast, and its stock surged about 12% on Wall Street. Growth in branded drugs offset a decline in generic sales.

Teva published its second-quarter 2026 results, surprising the market with better-than-expected performance. Revenue reached $4.1 billion, slightly below the same quarter last year but above analyst estimates. The decline is mainly due to the loss of exclusivity on the generic version of Revlimid in the US. In contrast, branded drugs Austedo (up 40%), Ajovy (56%), and Uzedy continued to grow rapidly. Following these results, Teva raised its sales forecast for these three drugs to $3.7 billion in 2026, as well as its overall revenue guidance. The company reported a loss of $576 million, but this was due to a one-time accounting impact from the acquisition of Emalex; excluding this expense, the quarter ended with a small profit. Investors reacted with a 12% surge in the stock at the opening of Wall Street trading. The article presents a narrative of recovery and success, emphasizing the strategy of transitioning to branded drugs.